kol call today et discuss nabriva nbrv
buy lefamulin anticip result
dial
strh biotech team host investor call key
opinion leader discuss lefamulin lefamulin current phase
clinic develop treatment moder sever
data leap first two phase studi announc
septemb top-lin data second phase studi
leap expect believ call valu add
investor address follow
mechan action
lefamulin fit within chang treatment paradigm
assess read-through leap base result
barrier entri base current commerci clinic
philip giordano recogn expert field
emerg medicin dr giordano sinc serv
chief corpor research oper orlando health
inc addit dr giordano serv vice chairman
depart emerg medicin orlando health inc sinc
dr giordano receiv medic degre univers
virginia school medicin complet resid
emerg medicin orlando health dr giordano board-
certifi emerg medicin american board
featur upsid slip develop mark
kitchen-sink neal dingmann
scale europ interout acquisit greg miller
 maintain hold rate materi posit increment
margin proven elus despit upsid total yoy
revenu growth yoy execut search
establish explicit target margin expans improv
return intern consult headcount growth could help
make us construct increas adj ep estim
et confer call discuss nabriva lefamulin
reflect
restructur cost save boost pt
earn preview margin return pois expand
recommend accumul share reiter pt
anticip fee revenu vs
consensu adj ep vs strh
model forese margin expans leverag
surg intern hire recent quarter medium term look
improv roe close
valuat discount group tobey sommer
solid result initi guidanc conserv
 report solid result in-lin better
expect initi guidanc number upsid lever
view expect compani outperform conserv
outlook throughout year combin capit
alloc build momentum us intern
though meaning outperform
expect firstnet-driven invest us
risen expect stock continu work upsid bia
guidanc maintain buy increas target greater
confid upsid estim greg miller
growth focu catalyst cabometyxsal
flat miss street increas
demand mask decreas distributor inventori
increas gross-to-net rcc slow focu
remain sale ramp kidney cancer io move
next month upsid expans drive
pt beyond rcc posit potenti
expans cobiin colorect cancer phase data
potenti expans liver cancer cabo io combo
valid data reiter buy rate pt
result mark posit volum trend hospit
ambulatori strong cash gener bump
guidanc compani continu make headway
divestitures/driv leverag qualiti cost save
addit cash flow profil look improv
remain cautious optimist given sizabl debt load
histor unev continu view execut key
maintain hold rate provid addit details/an
updat model follow call david macdonald
page
monitor last week soybean price increas
bushel higher soybean price could neg impact
compani univers cl
target roll forward estim
goe ep goe
introduc ebitda ep
price target goe target base
multipl ebitda previous
electr power util
estim base revis assumpt increas
estim factor higher estim
rais price target ali agha
kitchen-sink neal dingmann
leav hole fill result improv
oper incom revenu trend higher expect
rise ebitda margin back half growth
appear adequ price share
estim expect improv
beyond intern off-shore activ increas drive
demand high margin off-shore wellbor complet
product product servic see replac
estim ep gener see
tabl follow page maintain hold rate price
inc buy guid oilier
exit rate flat well fitzpatrick
improv econom though leverag still concern
 sanchez continu success delin comanch
 catarina includ recent stack develop
comanch area solid well econom comanch
see increas data show stronger estim result
howev price assumpt oil/gas/ngl
well could limit upsid given potenti lower price
overal compani valuat assum improv
financi could precari given averag leverag
 forecast free-cash-flow hit neal
page
preview upcom oper timelin lead discuss
 guidanc alreadi issu product
guidanc rang recent tighten would expect oper
updat drive discuss surround releas
look updat second hawkey well
permit area take-away regulatori environ
basin permit progress broomfield continu like
given high-return asset multipl upcom catalyst
investor like attun non-cor divestitur in-so-
much associ capital-expenditure increas caus mild concern
preview granular detail five-year outlook
help recent issu five-year outlook
pre-released volum given compani recent
shift eur cwc increment commentari well
econom could impact particular look
discuss around role compani n-la properti
long-term advanc marcellu setback n-la
result larger rel shift capit basin
drive major growth near-term well
featur upsid slip develop mark
inc buy miss current
quarter higher yield offset lower net origin
trim pt reiter hold rate main follow
anoth solid quarter result exceed expect across
metric envis compel scenario
would lead materi price-to-book multipl expans beyond current
increas nii/shar estim
reflect higher yield forecast introduc
nii/shar estim pt equat
vs peer reflect manag
impress execut attract exit valuat lower
growth focu catalyst cabometyxsal
flat miss street increas
demand mask decreas distributor inventori
increas gross-to-net rcc slow focu
page
remain sale ramp kidney cancer io move
next month upsid expans drive
pt beyond rcc posit potenti
expans cobiin colorect cancer phase data
potenti expans liver cancer cabo io combo
valid data reiter buy rate pt
result mark posit volum trend hospit
ambulatori strong cash gener bump
guidanc compani continu make headway
divestitures/driv leverag qualiti cost save
addit cash flow profil look improv
remain cautious optimist given sizabl debt load
histor unev continu view execut key
maintain hold rate provid addit details/an
updat model follow call david macdonald
remain earli label expans focu remain
approv larger ovarian cancer mainten set
howev rubraca revenu essenti flat expect
street reset growth expect treatment
set remov overhang addit expect
posit data multipl indic next month
push back commerci expect
prostat addit set believ stock
attract posit reset revenu potenti
posit news flow near term reiter buy reduc
pt peter lawson
bullish encompass follow strong mark
continu care coordin progress improv bad debt/
pre-claim denial re-affirmed guidanc addit cash
view well posit divis given
compani size sophist busi line synergi
competit advantag reiter buy rate
provid addit commentari updat model follow
call david macdonald
buy rate fm follow result mark solid
core trend despit meaning fx headwind upbeat
guidanc volum growth steadi across segment
coordin anoth impress margin improv
capit deploy opportun plenti second phase
global effici program drive savings/
effici reiter buy rate remain bullish core
page
trend provid addit details/upd model follow
call david macdonald
preview rang pipelin progress focal
point model sales/ep
ep rang
yoy growth midpoint sales/ep
street lower
tax rate expect xyrem volum growth normal
support jan pi potenti catalyst
includ vyxeo us ramp ema decis mid-year
solriamfetol fda decis late data
reiter ep
support dcf john bori
clear catalyst stay hold thought result
solid link guidanc seem reason despit anem
end market demand result zero book growth
recent effort appear deploy capit prudent
know underli econom acquir
busi view net cash outlay net gain
smart use capit although modesti
increas ep estim driven extern
lower tax rate pt remain unchang
maintain hold rate sandi draper
match pre-announce guidanc in-line item
call bruce nudel
compani buy verzenio abema
approv breast cancer week earlier expect
provid addit data support utrophin efficaci dmd
cotiv hold inc cotv buy see world
accord reiter buy share cotv
ytd compani finish
in-line quarter gave guidanc support street
think key stock continu work
consist execut dont need beat rais eas
concern guid note impli
organ healthcar growth higher
expect posit trend increas payment volum
greater payment complex remain mainstay driver
demand reiter buy given upsid potenti
pt sandi draper
page
inc buy chat
manag confer call brief discuss
regard mcot extend holter opportun
manag follow confer call takeaway
includ manag remain confid abl
hold mcot market share like make
concert effort extend holter segment
issuanc perman code reiter pt
ep bruce nudel
bluebird bio inc buy year
scd tdt bluebird expect deliv six clinic
data updat one regulatori file expect
posit outcom phase
studi lentiglobin transfusion-depend -thalassemia
tdt phase studi multipl myeloma
maintain pt remain bullish share
financi burosumab approv maintain hold
pt ec approv burosumab pediatr patient x-
link hypophosphatemia xlh februari
believ ultragenyx commerci prepar potenti
launch manag guid gradual market uptak
reimburs europ take month clinic
program track maintain hold rate watch
close balanc clinic commerci edward
guidanc leav littl surpris outlook
preview expect estim guidanc
yet reflect acquisit colfax fluid handl cfh
separ report segment call pump
maintain hold rate lower pt
follow disappoint revs/ep miss
expect management maintain revenu
outlook clear oper margin come year
trend lower larg negat increment gain lower
tax rate reduc oper margin estim
bp combin elev headcount ccc
underperfom plu side help push
backlog record co go-forward profit
profil appear compromis michael ciarmoli
page
reiter buy trade sinc report
result vs believ ebitda
guidanc investor expect ebitda
consensu neg impact
cariflex process issu headwind
previous expect account treatment
chang turnaround cost continu believ posit
develop kra busi
off-set constraint lead attract earn
remain under-valued opinion reiter buy
result look tax reform drive cycl stock
 mix releas margin
light view expect new break-out
segment show growth differ product
lower miner fiber unit dramat
expect assuag margin compress fear remain
buy stock given hope commerci renov
cycl spur tax reform rais pt
note product improv plan time
realiz like keith hugh
huntsman corpor buy evolv
consist gener gener
see achiev
driven robust polyurethan profit
continu step chang inventori manag
execut sinc dividend increas
signal confid outlook buy-back
market cap initi leverag like result
invest grade credit rate near term rais
target ebitda reiter
earn preview margin return pois expand
recommend accumul share reiter pt
anticip fee revenu vs
consensu adj ep vs strh
model forese margin expans leverag
surg intern hire recent quarter medium term look
improv roe close
valuat discount group tobey sommer
 maintain hold rate materi posit increment
margin proven elus despit upsid total yoy
revenu growth yoy execut search
page
establish explicit target margin expans improv
return intern consult headcount growth could help
make us construct increas adj ep estim
reflect
restructur cost save boost pt
 result guidanc unchang ss metric
expect guid bit light patrick schole
quarter expect bring ki bin
solid result initi guidanc conserv
 report solid result in-lin better
expect initi guidanc number upsid lever
view expect compani outperform conserv
outlook throughout year combin capit
alloc build momentum us intern
though meaning outperform
expect firstnet-driven invest us
risen expect stock continu work upsid bia
guidanc maintain buy increas target greater
confid upsid estim greg miller
scale europ interout acquisit greg miller
page
feb corpor group dinner cfo head ir new york
march unisi corpor ndr cfo vice-president ir new york new
mrch syntel inc synt ndr president/ceo vice-president financ head ir boston new
march wn hold ltd wn ndr corpor svp financ head ir mid-west
march group meet legacytexa group ltxb variou
march ndr ceo futurestep svp financ treasuri tax ir new york new
march coreciv inc ndr president/ceo manag director ir boston toronto
march central garden pet co ndr president/ceo vice-president ir/commun new york
march corp ndr ceo vice-president ir atlanta chicago
march ndr ceo/presid director ir mid-atlant
page
april nomad food limit nomd ndr ceo head ir new york
march texa bank field variou management team gnbc pb dalla
march group function enterpris connect orlando zoom orlando new
march shoptalk meet strh la vega
feb estimate conf call kol discuss nabriva lefamulin anticip result
march estimate conf call plc nbrv
march estimate conf call inc
page
march youssef squali nave khan internet/digit media mid-atlant
march jennif demba michael young bank dalla
march ki bin michael lewi greg miller reit boston
page
issu research report suntrust robinson humphrey inc analyst name report herebi certifi
recommend opinion express accur reflect research analyst person view
subject secur compani discuss herein part research analyst compens directli
indirectli relat specif recommend view express report
